Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin added to insulin therapy in adults with type 2 diabetes
IRCT20191231045959N2Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of sitagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Fasting blood sugar, 2-hour postprandial glucose and 5 more. Started Jun 2019; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20191231045959N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191231045959N2.